Ian Pike

Chief Scientific Officer

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ian Pike is the Chief Scientific Officer at Proteome Sciences plc in the UK. His research focuses on areas including tryptophan metabolism in glioblastoma, neurodegenerative disorders through circulating protein aggregates, and the role of MECP2 in neuroinflammation. Additionally, he has contributed to advancements in proteomics with the development of TMTpro reagents and has conducted biomarker studies related to Alzheimer's disease.

Articles (10)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (8)

Julie Dumont

Professor in cell biology and molecular genetics

Université de Lille

FRANCE

View details

Denise Sheer

Professor of Human Genetics

Barts and The London School of Medicine and Dentistry

UNITED KINGDOM

View details

Simon McArthur

Senior Lecturer in Neurosciences & Pharmacology

Queen Mary University of London

UNITED KINGDOM

View details

Henna Martiskainen

University of Eastern Finland

FINLAND

View details

Julien Chapuis

Université de Lille

FRANCE

View details

Devrim Kilinc

Institut Pasteur de Lille

FRANCE

View details

Audrey Coulon

Université de Lille

FRANCE

View details

Ville Leinonen

Professor

University of Oulu

FINLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ian Pike

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Analysis of circulating protein aggregates as a route of investigation into neurodegenerative disorders.

Correction to: Alzheimer's genetic risk factor FERMT2 (Kindlin-2) controls axonal growth and synaptic plasticity in an APP-dependent manner.

Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma.

MECP2 Increases the Pro-Inflammatory Response of Microglial Cells and Phosphorylation at Serine 423 Regulates Neuronal Gene Expression upon Neuroinflammation

TMTpro-18plex: The Expanded and Complete Set of TMTpro Reagents for Sample Multiplexing.

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.

Alzheimer's genetic risk factor FERMT2 (Kindlin-2) controls axonal growth and synaptic plasticity in an APP-dependent manner.

Author Correction: Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis.

Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator Approach.

TMTpro reagents: a set of isobaric labeling mass tags enables simultaneous proteome-wide measurements across 16 samples.

Collaborators (8)

Julie Dumont

Denise Sheer

Simon McArthur

Henna Martiskainen

Julien Chapuis

Devrim Kilinc

Audrey Coulon

Ville Leinonen

Make your next move.